Hesham Sheashaa, Kamal Awad, Arshad Mohammed, Juan M Farina, Mohammed Tiseer Abbas, Milagros Pereyra Pietri, Isabel G Scalia, Nima Baba Ali, Nadera N Bismee, Sogol Attaripour Esfahani, Omar Ibrahim, Fatmaelzahraa Abdelfattah, Ahmed K Mahmoud, Steven J Lester, David Simper, Chadi Ayoub, Reza Arsanjani
{"title":"Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study.","authors":"Hesham Sheashaa, Kamal Awad, Arshad Mohammed, Juan M Farina, Mohammed Tiseer Abbas, Milagros Pereyra Pietri, Isabel G Scalia, Nima Baba Ali, Nadera N Bismee, Sogol Attaripour Esfahani, Omar Ibrahim, Fatmaelzahraa Abdelfattah, Ahmed K Mahmoud, Steven J Lester, David Simper, Chadi Ayoub, Reza Arsanjani","doi":"10.1007/s40292-025-00727-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Lipoprotein(a) [Lp(a)] has been linked to myocardial fibrosis and endothelial dysfunction, proposed mechanisms for diastolic dysfunction (DD). This study assessed the association between elevated Lp(a) (≥ 50 mg/dL) and DD in patients with preserved ejection fraction (EF).</p><p><strong>Aim: </strong>We analyzed 1492 adults (median age59) with an Lp(a) measurement and echocardiogram (1997-2024).</p><p><strong>Methods: </strong>Diastolicdysfunction required ≥ 3 abnormal echo parameters, as per recent guidelines. Logisticregression adjusting for potential confounders was performed.</p><p><strong>Results: </strong>Seventy-sevenpatients (5.1%) had DD. Lp(a) ≥ 50 mg/dL was not associated with DD [adjusted oddsratio (aOR): 0.89, 95% confidence interval (CI): 0.49-1.54]. However, age (aOR:1.03, p = 0.026), hypertension (aOR: 1.83, p = 0.042), diabetes mellitus (aOR: 2.43, p =0.002), and cardiovascular (CV) diseases (aOR: 1.90, p = 0.043) were associated withDD, while statin therapy was associated with reduced risk (aOR: 0.51, p = 0.016).</p><p><strong>Conclusions: </strong>In the setting of preserved EF, Lp(a) was not associated with DD,emphasizing management of traditional CV risks.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"463-467"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-025-00727-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Lipoprotein(a) [Lp(a)] has been linked to myocardial fibrosis and endothelial dysfunction, proposed mechanisms for diastolic dysfunction (DD). This study assessed the association between elevated Lp(a) (≥ 50 mg/dL) and DD in patients with preserved ejection fraction (EF).
Aim: We analyzed 1492 adults (median age59) with an Lp(a) measurement and echocardiogram (1997-2024).
Methods: Diastolicdysfunction required ≥ 3 abnormal echo parameters, as per recent guidelines. Logisticregression adjusting for potential confounders was performed.
Results: Seventy-sevenpatients (5.1%) had DD. Lp(a) ≥ 50 mg/dL was not associated with DD [adjusted oddsratio (aOR): 0.89, 95% confidence interval (CI): 0.49-1.54]. However, age (aOR:1.03, p = 0.026), hypertension (aOR: 1.83, p = 0.042), diabetes mellitus (aOR: 2.43, p =0.002), and cardiovascular (CV) diseases (aOR: 1.90, p = 0.043) were associated withDD, while statin therapy was associated with reduced risk (aOR: 0.51, p = 0.016).
Conclusions: In the setting of preserved EF, Lp(a) was not associated with DD,emphasizing management of traditional CV risks.
期刊介绍:
High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.